Capricor Therapeutics Faces FDA Review Delay as Investors Prepare for Class Action Deadline

Recent Developments at Capricor Therapeutics

In a significant update for investors, Capricor Therapeutics, Inc. (NASDAQ: CAPR), renowned for its research in gene therapy for Duchenne muscular dystrophy (DMD), has found itself facing a crucial moment as the U.S. Food and Drug Administration (FDA) recently announced an extension in the review period for its Biologics License Application (BLA) regarding the investigational cell therapy, deramiocel. This decision shifts the PDUFA target action date from August 22, 2026, to November 22, 2026, sending ripples through investor circles.

Hagens Berman Sobol Shapiro LLP, a prominent plaintiffs' rights law firm, is alerting stakeholders that a lead plaintiff deadline is quickly approaching on September 28, 2026, as part of an ongoing securities class action aimed at uncovering potential wrongdoing by the company and its executives. The law firm is reaching out to those who have experienced significant losses in their investments related to Capricor, prompting them to seek justice and compensation for their financial difficulties.

Risks Surrounding the Review Extension

The FDA's extension does not come without complications. The agency's decision follows concerning findings from a turbulent Advisory Committee meeting held in July, where unsettling revelations about Capricor’s trial data and modifications to regulatory submissions were made. Specifically, the review is additionally focused on the content of Capricor's recent submissions, which include new data from a Phase 3 study (HOPE-3), illustrating a pivot toward concentrating solely on upper limb functionality.

Despite earlier positive assertions from Capricor regarding the efficacy of deramiocel, investors were rattled by conflicting evidence brought to light during the Advisory Committee's evaluation. As allegations began to circulate about misinformation pertaining to clinical trial outcomes and statistics adjustments that were allegedly made without FDA consent, the overall confidence in the firm started to wane.

Class Action Overview and Allegations

The class action revolves around a specified timeframe from December 17, 2025, to July 26, 2026, and revolves around allegations that Capricor, along with its leadership, made materially false and misleading statements about the BLA’s potential success and clinical trial data. Notably, disclosures indicated that Capricor did not obtain prerequisite agreement from the FDA concerning alterations to their statistical analysis plan (SAP).

On December 3, 2025, excitement sparked within investor circles after Capricor reported positive results from the HOPE-3 study. Market anticipation mounted, leading to a staggering surge in Capricor’s stock price, which skyrocketed 370%. Following this announcement, the firm opted to launch a public offering, providing around six million shares at a strikingly high price of $25 per share. However, this euphoric moment was short-lived.

When the FDA released briefing documents revealing that Capricor had made unauthorized changes to its study’s SAP, the stock price collapsed by nearly 64% in just one day, concluding at $7.00. The Advisory Committee subsequently voted against the drug's efficacy, ensuring losses compounded for investors.

Investor Responsibilities and Legal Options

In light of these developments, Hagens Berman is keen to facilitate potential class members in taking action by notifying them of their legal rights. Those who purchased or acquired Capricor securities during the indicated class period and suffered significant financial declines are encouraged to act swiftly, as the lead plaintiff designation is nearing its deadline. While seeking lead plaintiff status is not a prerequisite to receiving a potential settlement, contacting the firm is vital to understanding one’s options and rights.

If you're among those affected, you can reach out to Hagens Berman through their website or by phone for further assistance. In addition, the firm encourages individuals possessing sensitive or non-public information about Capricor to consider utilizing the SEC Whistleblower program, which could reward disclosures significantly.

Conclusion

As the review period continues to unfold at Capricor Therapeutics, the spotlight remains keenly focused on the biotech company's future and the consequences that may arise from the unfolding legal scenario. Investors should remain vigilant as they navigate through these present uncertainties. What becomes of deramiocel and its promise for DMD treatment may very likely depend on the actions that both the company and its investors take in the upcoming weeks.